Cirtec Medical, Brooklyn Park, Minnesota, has received the first commercial batch of Stereax solid-state battery electrodes from Ilika, Southampton, United Kingdom, for Stereax M300 production. The delivery fulfills the first revenue-generating order under a commercial supply arrangement initiated in January 2026.<\/p>\n
The electrodes will support Stereax M300 batteries used in validation and customer sampling across multiple active implantable medical device categories, including implanted sensors, neurostimulators, orthopedic implants, orthodontic wearables, and ophthalmology devices. The Stereax M300 is an ultra-thin, millimeter-scale, rechargeable solid-state battery containing no liquid or polymer components, designed specifically for implantable applications.<\/p>\n
“Our close technical cooperation with Ilika has developed into an effective operational partnership, ensuring customers receive the highest quality product for device integration,” said Shawn Martin, Vice President at Cirtec Medical.<\/p>\n
Cathode manufacturing remains at Ilika’s UK facility as the most complex production step, while primary battery manufacturing occurs at Cirtec’s facility in Lowell, Massachusetts. The milestone marks Ilika’s transition from technology development to commercial supply in the medical device battery market.<\/p>\n
[www.cirtecmed.com](https:\/\/www.cirtecmed.com)<\/p>\n","protected":false},"excerpt":{"rendered":"